Discovery offers insight for development of cancer therapies targeting mutant p53
Hong Kong dismisses business pushback over ‘zero-COVID’ strategy
31 August 2021Autistic individuals have increased risk of COVID-19
31 August 2021Discovery offers insight for development of cancer therapies targeting mutant p53
The tumor suppressor protein p53 is mutated in more than half of all human cancers. Several drugs that potentially can restore mutant p53 to its normal cancer-killing function are in clinical investigation.
